AI Engines For more Details: Perplexity Kagi Labs You
Giardiasis: Secnidazole is effective in the treatment of giardiasis, a parasitic infection of the small intestine caused by the protozoan Giardia lamblia. Symptoms of giardiasis include diarrhea, abdominal cramps, bloating, nausea, and weight loss. Secnidazole works by disrupting the DNA structure of the parasite, leading to its death and elimination from the body.
Trichomoniasis: Trichomoniasis is a sexually transmitted infection caused by the protozoan parasite Trichomonas vaginalis. It primarily affects the urogenital tract in both men and women, leading to symptoms such as vaginal discharge, genital itching, burning during urination, and urethral discharge in men. Secnidazole is effective in treating trichomoniasis by eradicating the parasite from the body.
Amoebiasis: Secnidazole is also used in the treatment of amoebiasis, an infection caused by the protozoan parasite Entamoeba histolytica. Amoebiasis primarily affects the intestines, leading to symptoms such as diarrhea (which may be bloody), abdominal pain, cramping, and fever. By targeting the DNA of the parasite, secnidazole helps eliminate the infection and alleviate symptoms associated with amoebiasis.
Single-Dose Treatment: One of the advantages of secnidazole is its ability to achieve therapeutic efficacy with a single-dose regimen in many cases. This convenience makes it a preferred treatment option for certain protozoal infections, particularly trichomoniasis.
Safety and Tolerability: Secnidazole is generally well-tolerated, with adverse effects being mild and transient. Common side effects may include nausea, vomiting, abdominal discomfort, headache, dizziness, and metallic taste in the mouth. These side effects usually resolve on their own and do not require discontinuation of treatment.
Dosage and Administration: The dosage of secnidazole may vary depending on the specific infection being treated, the severity of symptoms, and individual patient factors. It is typically administered orally in the form of tablets or suspensions. Patients should follow their healthcare provider's instructions regarding dosage and duration of treatment.
Contraindications and Precautions: Secnidazole is contraindicated in patients with known hypersensitivity to the medication or its components. It should be used with caution in patients with a history of seizures or neurological disorders. Additionally, secnidazole should be avoided during pregnancy and lactation unless the potential benefits outweigh the risks.
Drug Interactions: There are limited reports of significant drug interactions with secnidazole. However, it is always important for patients to inform their healthcare providers about all medications, supplements, and herbal products they are taking before starting treatment with secnidazole.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bacteroides uniformis | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
Acne | 0.3 | -0.3 | |
ADHD | 4.7 | 0.6 | 6.83 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 2.5 | 1.9 | 0.32 |
Allergies | 6.3 | 4.2 | 0.5 |
Allergy to milk products | 2 | 1 | 1 |
Alopecia (Hair Loss) | 1.6 | 1.6 | |
Alzheimer's disease | 6.9 | 7.4 | -0.07 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 0.9 | 3.11 |
Ankylosing spondylitis | 3.8 | 1.8 | 1.11 |
Anorexia Nervosa | 1.4 | 2.9 | -1.07 |
Antiphospholipid syndrome (APS) | 1.2 | 0.3 | 3 |
Asthma | 5 | 3 | 0.67 |
Atherosclerosis | 2.1 | 2.4 | -0.14 |
Atrial fibrillation | 3.8 | 2.5 | 0.52 |
Autism | 11 | 10.3 | 0.07 |
Autoimmune Disease | 0.3 | 1 | -2.33 |
Barrett esophagus cancer | 0.6 | 0.6 | |
benign prostatic hyperplasia | 0.3 | -0.3 | |
Biofilm | 1.5 | 1.5 | |
Bipolar Disorder | 1.8 | 1.7 | 0.06 |
Brain Trauma | 0.6 | 1.4 | -1.33 |
Breast Cancer | 0.6 | 0.6 | |
Cancer (General) | 0.9 | 3.3 | -2.67 |
Carcinoma | 4.1 | 2.6 | 0.58 |
Celiac Disease | 2.7 | 4.3 | -0.59 |
Cerebral Palsy | 1.6 | 1.3 | 0.23 |
Chronic Fatigue Syndrome | 5.7 | 7.4 | -0.3 |
Chronic Kidney Disease | 4.6 | 3.4 | 0.35 |
Chronic Lyme | 0.6 | 0.8 | -0.33 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.7 | -0.89 |
Chronic Urticaria (Hives) | 0.5 | 1.8 | -2.6 |
Coagulation / Micro clot triggering bacteria | 0.4 | 1 | -1.5 |
Cognitive Function | 2.8 | 1.3 | 1.15 |
Colorectal Cancer | 6.2 | 2.2 | 1.82 |
Constipation | 1.5 | 0.7 | 1.14 |
Coronary artery disease | 1.5 | 3 | -1 |
COVID-19 | 10.5 | 13.9 | -0.32 |
Crohn's Disease | 8.9 | 6.9 | 0.29 |
Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
cystic fibrosis | 1.8 | -1.8 | |
deep vein thrombosis | 2 | 1.1 | 0.82 |
Denture Wearers Oral Shifts | 1.2 | 1.2 | |
Depression | 11.9 | 10.7 | 0.11 |
Dermatomyositis | 0.3 | -0.3 | |
Eczema | 1.4 | 1.6 | -0.14 |
Endometriosis | 2 | 2 | 0 |
Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
Epilepsy | 3 | 2.8 | 0.07 |
erectile dysfunction | 0.8 | 0.3 | 1.67 |
Fibromyalgia | 3.7 | 2.6 | 0.42 |
Functional constipation / chronic idiopathic constipation | 5.4 | 4.9 | 0.1 |
gallstone disease (gsd) | 3.1 | 1.6 | 0.94 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 0.9 | 1.67 |
Generalized anxiety disorder | 2.4 | 2.2 | 0.09 |
giant cell arteritis | 0.2 | -0.2 | |
Gout | 2.3 | 1 | 1.3 |
Graves' disease | 1.9 | 3 | -0.58 |
Gulf War Syndrome | 0.6 | 2.6 | -3.33 |
Halitosis | 1.5 | 1.5 | |
Hashimoto's thyroiditis | 4.4 | 2.2 | 1 |
Heart Failure | 3.9 | 2.4 | 0.63 |
hemorrhagic stroke | 1.3 | 1.3 | |
Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
hyperglycemia | 1.2 | 2.2 | -0.83 |
Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
hypersomnia | 0.7 | -0.7 | |
hypertension (High Blood Pressure | 4.9 | 6.4 | -0.31 |
Hypothyroidism | 0.5 | 1 | -1 |
Hypoxia | 2.9 | 0.3 | 8.67 |
IgA nephropathy (IgAN) | 1.6 | 5.5 | -2.44 |
Inflammatory Bowel Disease | 8.9 | 11.1 | -0.25 |
Insomnia | 1.6 | 3.2 | -1 |
Intelligence | 1.4 | 0.6 | 1.33 |
Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
Irritable Bowel Syndrome | 8.5 | 6.1 | 0.39 |
ischemic stroke | 2.3 | 1.1 | 1.09 |
Liver Cirrhosis | 7.1 | 5.1 | 0.39 |
Long COVID | 7.9 | 9.2 | -0.16 |
Low bone mineral density | 1.1 | -1.1 | |
Lung Cancer | 0.9 | 1.6 | -0.78 |
Mast Cell Issues / mastitis | 0.6 | 0.9 | -0.5 |
ME/CFS with IBS | 0.8 | 2.4 | -2 |
ME/CFS without IBS | 1.7 | 2.4 | -0.41 |
Menopause | 1.7 | 1 | 0.7 |
Metabolic Syndrome | 8 | 9.2 | -0.15 |
Mood Disorders | 12.4 | 8.6 | 0.44 |
multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
Multiple Sclerosis | 6.9 | 6.7 | 0.03 |
Multiple system atrophy (MSA) | 1.7 | 0.7 | 1.43 |
myasthenia gravis | 0.7 | -0.7 | |
neuropathic pain | 0.3 | 3.6 | -11 |
Neuropathy (all types) | 0.9 | 1.6 | -0.78 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 5.8 | -0.16 |
NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
Obesity | 11.4 | 9.6 | 0.19 |
obsessive-compulsive disorder | 5.5 | 4.6 | 0.2 |
Osteoarthritis | 2.4 | 1.4 | 0.71 |
Osteoporosis | 1.9 | 1.6 | 0.19 |
pancreatic cancer | 0.9 | 0.9 | |
Parkinson's Disease | 8.5 | 7.4 | 0.15 |
Polycystic ovary syndrome | 7 | 3.4 | 1.06 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
Primary sclerosing cholangitis | 2.1 | 3.2 | -0.52 |
Psoriasis | 3.5 | 4 | -0.14 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.7 | 4.7 | 0.85 |
Rosacea | 1.2 | 0.7 | 0.71 |
Schizophrenia | 7.5 | 3.6 | 1.08 |
scoliosis | 0.3 | 1.2 | -3 |
Sjögren syndrome | 2.3 | 3.1 | -0.35 |
Sleep Apnea | 2.2 | 1.8 | 0.22 |
Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
Stress / posttraumatic stress disorder | 3.1 | 3.3 | -0.06 |
Systemic Lupus Erythematosus | 4 | 2.4 | 0.67 |
Tic Disorder | 1.2 | 1.8 | -0.5 |
Tourette syndrome | 1.1 | 0.3 | 2.67 |
Type 1 Diabetes | 4.2 | 4 | 0.05 |
Type 2 Diabetes | 9 | 8 | 0.13 |
Ulcerative colitis | 5.5 | 8.8 | -0.6 |
Unhealthy Ageing | 6.5 | 2.9 | 1.24 |
Vitiligo | 2.2 | 2 | 0.1 |